Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02108262 · ClinicalTrials.gov registry record · Phase 2
A Phase 2b Study of CSL112 in Subjects With Acute Myocardial Infarction.
A Phase 2 study, sponsored by CSL Behring.
- Completed
- Registry status
- Phase 2
- Development phase
- 1,267
- Enrollment target
NCT02108262 is a Phase 2 study that has completed, run by CSL Behring. The registered enrollment target is 1,267 participants.
The verdict
NCT02108262, a Phase 2 study, has completed, sponsored by CSL Behring.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 1,267 participants
- Enrollment target
Study Summary
This is a multicenter randomized, double-blind, placebo-controlled, parallel-group, dose-ranging phase 2b study to investigate the hepatic and renal safety and tolerability of multiple dose administration of two dose levels of CSL112 compared with placebo in subjects with acute myocardial infarction (AMI).
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL CSL112
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,267 participants |
| Start Date | 2014-08 |
| Est. Completion | 2016-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02108262
The ClinicalTrials.gov registry entry for NCT02108262 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 1,267 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is CSL Behring, which has 71 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02108262 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02108262 about?
NCT02108262 is a clinical study titled "A Phase 2b Study of CSL112 in Subjects With Acute Myocardial Infarction.". This is a multicenter randomized, double-blind, placebo-controlled, parallel-group, dose-ranging phase 2b study to investigate the hepatic and renal safety and tolerability of multiple dose administration of two dose levels of CSL112 compared with placebo in subjects with acute myocardial infarction...
What is the current status of trial NCT02108262?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 1,267 participants. The study started on 2014-08. Estimated completion is 2016-03.
What interventions are being tested in trial NCT02108262?
The interventions under investigation include: Placebo (BIOLOGICAL), CSL112 (BIOLOGICAL).
Who is sponsoring clinical trial NCT02108262?
This trial is sponsored by CSL Behring, which has 71 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.